BeOne Medicines (NASDAQ:ONC) Price Target Raised to $454.00 at TD Cowen

BeOne Medicines (NASDAQ:ONC) had its price target lifted by investment analysts at TD Cowen from $424.00 to $454.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price target suggests a potential upside of 37.87% from the company’s previous close.

A number of other brokerages also recently commented on ONC. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Wells Fargo & Company began coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Royal Bank Of Canada lowered their price objective on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Nomura raised BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and an average price target of $400.00.

BeOne Medicines Trading Up 0.5%

NASDAQ ONC traded up $1.77 on Thursday, reaching $329.30. 186,427 shares of the company were exchanged, compared to its average volume of 280,046. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The business’s fifty day moving average price is $294.53 and its 200 day moving average price is $308.67. The stock has a market capitalization of $36.13 billion, a P/E ratio of 73.51 and a beta of 0.49. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. Analysts forecast that BeOne Medicines will post 5.93 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO John Oyler sold 145,861 shares of BeOne Medicines stock in a transaction on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the sale, the chief executive officer directly owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the completion of the sale, the chief operating officer owned 40 shares in the company, valued at $10,774.80. This represents a 97.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 345,561 shares of company stock worth $105,625,947 over the last 90 days. 6.19% of the stock is owned by insiders.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of ONC. Mariner LLC grew its holdings in shares of BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after purchasing an additional 32 shares in the last quarter. Signaturefd LLC grew its stake in shares of BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after acquiring an additional 33 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after acquiring an additional 39 shares in the last quarter. CWM LLC increased its position in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Steadtrust LLC raised its stake in shares of BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after acquiring an additional 50 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines News Roundup

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings beat estimates: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat supports the view that the company’s oncology portfolio is delivering stronger profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above Wall Street’s $6.5 billion forecast. Reports also indicated that second-quarter revenue surged 30%, reinforcing expectations for continued commercial momentum. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analysts raised targets and maintained bullish ratings: Guggenheim raised its target to $430 and Truist lifted its target to $418, both with Buy ratings. Citizens JMP raised its target to $405 with a Market Outperform rating. RBC trimmed its target slightly to $450 but retained an Outperform rating. These targets imply substantial upside from recent trading levels. Analyst rating updates
• Positive Sentiment: Pipeline progress: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale appears administrative: CFO Aaron Rosenberg sold 1,157 shares worth approximately $362,000 to cover tax withholding related to vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.